{"id":78583,"date":"2025-04-24T08:14:31","date_gmt":"2025-04-24T06:14:31","guid":{"rendered":"https:\/\/www.ipsen.com\/press-releases\/les-dernieres-donnees-sur-lelafibranor-demontrent-un-profil-de-tolerance-favorable-et-une-efficacite-significative-dans-la-csp-une-deuxieme-indication-dans-les-maladies-rares-du-foie-3067100\/"},"modified":"2025-04-24T08:14:31","modified_gmt":"2025-04-24T06:14:31","slug":"les-dernieres-donnees-sur-lelafibranor-demontrent-un-profil-de-tolerance-favorable-et-une-efficacite-significative-dans-la-csp-une-deuxieme-indication-dans-les-maladies-rares-du-foie-3067100","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/fr\/press-releases\/les-dernieres-donnees-sur-lelafibranor-demontrent-un-profil-de-tolerance-favorable-et-une-efficacite-significative-dans-la-csp-une-deuxieme-indication-dans-les-maladies-rares-du-foie-3067100\/","title":{"rendered":"Les derni\u00e8res donn\u00e9es sur l\u2019\u00e9lafibranor d\u00e9montrent un profil de tol\u00e9rance favorable et une efficacit\u00e9 significative dans la CSP, une deuxi\u00e8me indication dans les maladies rares du foie"},"content":{"rendered":"